Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.71 |
| ▸ | FAAH | O00519 | 5/20 | 0.68 |
| ▸ | NAAA | Q02083 | 1/20 | 0.67 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.61 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.59 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30970182 | 1.00 | CASP2 (0.71) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL15369060 | 1.00 | CASP2 (0.71) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL20909276 | 1.00 | CASP2 (0.71) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL12250891 | 1.00 | CASP2 (0.71) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL15003766 | 1.00 | CASP2 (0.71) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL22221624 | 0.98 | CASP2 (0.69) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL24155324 | 0.96 | CASP2 (0.71) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL18627446 | 0.96 | CASP2 (0.71) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL30970230 | 0.96 | FAAH (0.68) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL23344139 | 0.96 | FAAH (0.68) | CASP2FAAHNAAADNM1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3922260-A2 | INSULIN RECEPTOR PARTIAL AGONISTS AND GLP-1 ANALOGUES | MERCK SHARP & DOHME CORP. (US) | 2021-12-15 | — | — | EP | disclosed |
| EP-3221343-B1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME (US) | 2020-09-16 | — | — | EP | disclosed |
| EP-3666792-A2 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-06-17 | — | — | EP | disclosed |
| EP-3660041-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-06-03 | — | — | EP | disclosed |
| EP-3660040-A2 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-06-03 | — | — | EP | disclosed |
| US-20190038658-A1 | HIGH DENSITY LIPOPROTEIN BINDING PROTEIN (HDLBP/VIGILIN) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2019-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190038658-A1 | HIGH DENSITY LIPOPROTEIN BINDING PROTEIN (HDLBP/VIGILIN) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | HDLBP, LDLR, IGF2BP1 | CASP2 4630/4885FAAH 3826/4885NAAA 3653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.